1stOncology™: Cancer Intelligence Service – Page 11169 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Appili Therapeutics to Participate in Upcoming Investor Conferences for H.C. Wainwright & Co. and Maxim Group LLC

On September 10, 2020 Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, reported that its leadership team will be presenting an update on Appili’s programs at two upcoming investor conferences (Press release, Appili Therapeutics, SEP 10, 2020, View Source [SID1234564975]). A copy of Appili’s investor presentation will be available on the Company’s website under the ‘Investor Overview’ page.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details are as follows:

H.C. Wainwright & Co – 22nd Annual Global Investment Conference
Date: Tuesday, September 15
Time: 4:00 PM ET
Access via Webcasting Link: View Source
About the Conference
H.C. Wainwright & Co’s 22nd Annual Global Investment Conference is a virtual event occurring September 14-16, 2020. It includes leading industry keynote speakers and presenting companies, investor one-on-one meetings, networking opportunities with attendees, and an evening of virtual entertainment.

Maxim Group’s Antifungal Webinar
Title: A Too Quiet Pandemic – Fungal Disease
Date: Thursday, September 17
Time: 1:00 PM ET
Access: https://bit.ly/3bDWHJ9
About the Conference
With much of the mainstream focus on antibiotic drug resistance and viral diseases, fungi and their related invasive and mucosal infections still seem to go relatively unnoticed. There are over 1.6 million deaths annually related to severe fungal infections and there are tens of millions of mucosal infections. The need for new anti-infectives could never be greater, especially antifungals where there are only three existing classes of drugs with too few options in each. Fungal-driven diseases are diseases of opportunity, often arising in settings of immune function changes or secondary to other conditions like cancer therapy and transplant, even secondary to viral infections including COVID-19. However, while these are diseases of opportunity for fungi and representative of its own pandemic, with it comes opportunity for novel therapeutics to emerge. The unmet need has ushered in not only innovative approaches, but also changes in regulatory guidelines, incentives for drug developers, changes in trial design and execution, changes in the views of payers and renewed focus of the investment community. This panel discussion includes top innovators in the fungal drug development space.

BiomX to Present at Upcoming September Investor Conferences

On September 10, 2020 BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, reported that Jonathan Solomon, Chief Executive Officer, will participate in the following upcoming investor conferences (Press release, BiomX, SEP 10, 2020, View Source [SID1234564974]).

Event: HC Wainwright 22nd Annual Global Investments Conference
Date: Monday, Sept. 14, 2020
Time: 12:30 p.m. EDT
Webcast link: View Source

Event: Cantor 2020 Virtual Global Healthcare Conference
Date: Wednesday, Sept. 16, 2020
Time: 11:20 a.m. EDT
Webcast link: View Source

Webcasts will also be available in the Events section of the BiomX website at www.biomx.com. Archived replays will be accessible following each event.

Verastem Oncology to Present at Upcoming Investor Conferences

On September 10, 2020 Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, reported that management will present virtually at the following upcoming investor conferences (Press release, Verastem, SEP 10, 2020, View Source [SID1234564973]):

H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 1:30 p.m. Eastern Time
Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 3:20 p.m. Eastern Time
A live webcast of the presentations will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.

Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences

On September 10, 2020 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) reported that senior management will be presenting and hosting one-on-one meetings at the following investor conferences (Press release, Aldeyra Therapeutics, SEP 10, 2020, View Source [SID1234564972]):

H.C. Wainwright 22nd Annual Global Investment Conference
Presentation Date: Monday, September 14, 2020
Time: 3:30 p.m. ET
2020 Cantor Global Virtual Healthcare Conference
Presentation Date: Wednesday, September 16, 2020 (Fireside Chat)
Time: 2:40 p.m. ET
A live webcast of the presentations will be available on the investor relations page of the company’s corporate website at View Source After the live webcast, the events will remain archived on the Aldeyra Therapeutics website for 90 days.

ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers

On September 10, 2020 ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, reported that preclinical data related to camidanlumab tesirine (Cami, formerly ADCT-301) has been published in the Journal for ImmunoTherapy of Cancer, the online journal of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), in a paper titled, "CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity (Press release, ADC Therapeutics, SEP 10, 2020, View Source [SID1234564971])."

The study evaluated the antitumor activity of a pyrrolobenzodiazepine (PBD) dimer-based, CD25-targeted ADC, either alone or in combination with a checkpoint inhibitor, in CD25-negative syngeneic colon cancer models that exhibit tumor infiltration of CD25-expressing regulatory T cells (Tregs). Data demonstrated that single low doses of the CD25-targeted ADC resulted in potent and durable antitumor activity against established CD25-negative solid tumors with infiltrating Tregs, both as a monotherapy and in combination with an anti-PD1 checkpoint inhibitor.

Patrick van Berkel, Ph.D., Senior Vice President of Research and Development at ADC Therapeutics, said, "CD25 is expressed on Tregs that infiltrate the local tumor environment. We were pleased to see that our CD25-targeted ADC depleted CD25-expressing Tregs and not only showed strong anti-tumor activity as a monotherapy in preclinical models, but it also enhanced the activity of anti-PD1 treatment in these models. This study provides proof of concept for a new application of ADCs as immunotherapeutic agents and supports the continued evaluation of Cami in our ongoing Phase 1b clinical trial in patients with selected advanced solid tumors. We look forward to advancing the exploration of Cami as a novel immune-oncology approach for the treatment of solid tumors."

For information about the company’s Phase 1b clinical trial of Cami in solid tumors, visit www.clinicaltrials.gov (identifier NCT03621982).

About Camidanlumab Tesirine (Cami)

Camidanlumab tesirine (Cami, formerly ADCT-301) is an antibody drug conjugate (ADC) comprised of a monoclonal antibody that binds to CD25 (HuMax-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine. Once bound to a CD25-expressing cell, ADCT-301 is internalized into the cell where enzymes release the PBD-based warhead killing the cell. This applies to CD25-expressing tumor cells, and also to CD25-expressing Tregs. The intra-tumoral release of its PBD warhead may also cause bystander killing of neighboring tumor cells and PBDs have also been shown to induce immunogenic cell death. All these properties of Cami may enhance immune-mediated anti-tumor activity. Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma (HL), as well as in a Phase 1a/1b clinical trial in patients with relapsed or refractory HL and non-Hodgkin lymphoma and a Phase 1b clinical trial in solid tumors.